ArticleFrontiers in pharmacology2025
Low-molecular-weight heparins utilization in pregnant and postpartum women: a real-world analysis in China (2016-2021).
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A novel predictive model for evaluating thrombus regression in postpartum venous thromboembolism patients.International journal of clinical pharmacy · 2026Article
- Therapeutic role of low molecular weight heparin and fat-soluble vitamins in pregnancy-associated prethrombotic conditions.Frontiers in medicine · 2026Review
- Knowledge, attitudes, and practices on venous thromboembolism among maternal women and analysis of influencing factors: a cross-sectional study in Southwest China.BMC pregnancy and childbirth · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to examine trends in low-molecular-weight heparin (LMWH) use for managing pregnancy-associated venous thromboembolism (VTE) and to explore the correlation between pregnancy-related VTE risk factors and LMWH prescription rates. Methods: This was a cross-sectional study that analyzed prescription data from pregnant and postpartum women using LMWH to manage VTE, collected during 2016-2021. Risk factors associated with VTE were analyzed. Separately comparing the number of prescriptions, prescription cost, defined daily doses (DDDs), and defined daily cost (DDC) of seven LMWH. Results: This study included 41,885 prescriptions, with the average age of patients being 32 ± 4.69 years old. The most common risk factors for VTE during pregnancy and the postpartum period in this study included advanced age (>35 years old), cesarean section, diabetes, miscarriage, and preterm birth, accounting for 28.61%, 25.60%, 18.34%, 17.31%, and 13.63% respectively. There was a 173% increase in LMWH prescription costs during the study period. In terms of number of prescriptions, prescription cost, and DDDs, enoxaparin sodium, nadroparin calcium, and low-molecular-weight heparin calcium consistently ranked in the top three from 2019 to 2021. In terms of DDC, low-molecular-weight heparin sodium, dalteparin sodium, and enoxaparin sodium were the lowest. Conclusion: From 2016 to 2021, both the number of prescriptions and the total prescription costs for the management of VTE during pregnancy and the postpartum period increased. Enoxaparin sodium, nadroparin calcium, and low-molecular-weight heparin calcium were the most common LMWH. Advanced age (>35 years old), cesarean section, diabetes, miscarriage, and preterm birth were the most common pregnancy-related VTE risk factors linked to LMWH prescription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.